| Drug General Information |
| Drug ID |
D0G4OT
|
| Former ID |
DCL001039
|
| Drug Name |
XL784
|
| Indication |
Diabetic nephropathy [ICD9: 250.4; ICD10:E11.21]
|
Discontinued in Phase 2 |
[1]
|
|---|
| Company |
Exelixis
|
| Target and Pathway |
| Target(s) |
Interstitial collagenase |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
PPAR signaling pathway
|
|
Pathways in cancer
|
|
Bladder cancer
|
|
Rheumatoid arthritis
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
TWEAK Signaling Pathway
|
|
Wnt Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-presenilin pathway
|
|
Plasminogen activating cascade
|
|
Pathway Interaction Database
|
Endothelins
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Glucocorticoid receptor regulatory network
|
|
AP-1 transcription factor network
|
|
Syndecan-1-mediated signaling events
|
|
Reactome
|
Collagen degradation
|
|
Degradation of the extracellular matrix
|
|
Activation of Matrix Metalloproteinases
|
|
Basigin interactions
|
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
|
WikiPathways
|
TGF beta Signaling Pathway
|
|
Bladder Cancer
|
|
Activation of Matrix Metalloproteinases
|
|
Degradation of collagen
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
Oncostatin M Signaling Pathway
|
|
Prostate Cancer
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Cell surface interactions at the vascular wall
|
|
Matrix Metalloproteinases
|
| References |
| REF 1 | Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63. |
|---|
